Annals of the rheumatic diseases
Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.
Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.
Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
Short-chain fatty acids and their gut microbial pathways distinguish rheumatoid arthritis in discordant monozygotic twins.
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
ASAS recommendations on reporting axial spondyloarthritis clinical trials.
ABS0706 SUSTAINABILITY OF CLINICAL RESPONSE THROUGH 2 YEARS AMONG UPADACITINIB-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE SELECT-AXIS 1 AND SELECT-AXIS 2 TRIALS.
POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES.
POS0864 ACHIEVEMENT OF REMISSION DEFINED BY ABSENCE OF OBJECTIVE SIGNS OF INFLAMMATION VERSUS ASDAS INACTIVE DISEASE IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES.
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION.
